Literature DB >> 18339789

Burden of concomitant asthma and COPD in a Medicaid population.

Fadia T Shaya1, Du Dongyi, Manabu O Akazawa, Christopher M Blanchette, Jingshu Wang, Douglas W Mapel, Anand Dalal, Steven M Scharf.   

Abstract

BACKGROUND: Asthma and COPD can significantly affect patients and pose a substantial economic burden for both patients and managed-care plans. This study compares utilization outcomes in patients with asthma, COPD, or co-occurring asthma and COPD in a Medicaid population, and assesses the incremental burden of COPD in patients with asthma.
METHODS: We queried medical claims of Medicaid patients aged 40 to 64 years with asthma and/or COPD filed between January 1, 2001, and December 31, 2003, from encounter data. COPD patients were identified based on at least one claim with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes 491, 492, 496; and asthma patients were identified on the basis of ICD-9 code 493 as diagnosis. We analyzed annual utilization and cost of hospitalizations, physician, and outpatient services attributable to asthma and/or COPD.
RESULTS: The analysis included a total of 3,072 asthma, 3,455 COPD, and 2,604 COPD/asthma patients. COPD/asthma co-occurring disease has higher utilization of any service type than either disease alone. Compared with asthma patients, COPD patients were 16% and 51% more likely to use physician (odds ratio [OR], 1.16; 95% confidence interval [CI], 1.01 to 1.34) and inpatient services (OR, 1.51; 95% CI, 1.31 to 1.74), respectively; and 60% less likely to use outpatient services (OR, 0.40; 95% CI, 0.35 to 0.46). Compared with asthma patients, COPD patients and COPD/asthma co-occurring patients cost 50% (OR, 1.50; 95% CI, 1.3 to 1.74) and five times (OR, 5.25; 95% CI, 4.59 to 6.02) more for total medical services, respectively.
CONCLUSION: Our data suggest that patients with COPD and co-occurring COPD/asthma were sicker and used more medical services than asthma patients. The incremental burden of COPD to patients with asthma is significant.

Entities:  

Mesh:

Year:  2008        PMID: 18339789     DOI: 10.1378/chest.07-2317

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  39 in total

1.  The economic burden of medical care in general and sleep apnea syndrome in particular.

Authors:  Vidya Krishnan
Journal:  Sleep Breath       Date:  2009-05-30       Impact factor: 2.816

Review 2.  Pharmacogenomics of chronic obstructive pulmonary disease.

Authors:  Craig P Hersh
Journal:  Expert Rev Respir Med       Date:  2019-04-08       Impact factor: 3.772

3.  Utilization, spending, and price trends for short- and long-acting Beta-agonists and inhaled corticosteroids in the medicaid program, 1991-2010.

Authors:  Shih-Feng Chiu; Christina M L Kelton; Jeff Jianfei Guo; Patricia R Wigle; Alex C Lin; Sheryl L Szeinbach
Journal:  Am Health Drug Benefits       Date:  2011-05

4.  Asthma and Chronic Obstructive Pulmonary Disease Overlap: The Effect of Definitions on Measures of Burden.

Authors:  David M Mannino; Wen Oi Gan; Keele Wurst; Kourtney J Davis
Journal:  Chronic Obstr Pulm Dis       Date:  2017-02-03

Review 5.  The Reemergence of the Asthma-COPD Overlap Syndrome: Characterizing a Syndrome in the Precision Medicine Era.

Authors:  Stephanie A Christenson
Journal:  Curr Allergy Asthma Rep       Date:  2016-11       Impact factor: 4.806

Review 6.  Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care.

Authors:  David B Price; Barbara P Yawn; Rupert C M Jones
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

Review 7.  Epidemiology of the origins of airflow limitation in asthma.

Authors:  Stefano Guerra; Fernando D Martinez
Journal:  Proc Am Thorac Soc       Date:  2009-12

Review 8.  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Authors:  Barbara P Yawn; Ibrahim Raphiou; Judith S Hurley; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

Review 9.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

Review 10.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.